Notice of Results and Investor Presentation

28 May 2026

Ondine Biomedical Inc.

("Ondine" or the "Company")

Notice of Results and Investor Presentation

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited results for the year ended 31 December 2025 ("Full Year Results") and Annual Report 2025 on 4 June 2026.

Dr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas, Chief Financial Officer, will host a presentation and live Q&A session relating to the Full Year Results via Investor Meet Company on 4 June 2026 at 16:30 BST (08:30 Pacific time).

The presentation is open to all sell-side analysts, existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 3 June 2026, 09:00 BST (01:00 Pacific time), or at any time during the presentation.

Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via:

https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.

A full overview of the 2025 fiscal year will be presented in the Annual Report 2025, which will be available on the Company's website on 4 June 2026 at: www.ondinebio.com/investors/reports-documentation. The slides and recording of the live presentation will be posted to the same webpage as soon as available following the presentation, no later than 5 June 2026.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico, and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

U.S. Regulatory Status Disclaimer

​

Steriwave® is CE-marked in Europe and is approved for nasal decolonisation in Canada, the United Kingdom, Australia, and Mexico. In the United States, Steriwave has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track status by the U.S. Food and Drug Administration (FDA). It is currently undergoing clinical trials in the United States to support regulatory approval and is limited by United States law to investigational use only. It is not commercially available for sale or clinical use in the United States.